Published in final edited form as:

Mol Nutr Food Res. 2012 November ; 56(11): . doi:10.1002/mnfr.201200276.

Inhibition of Bladder Cancer by Broccoli Isothiocyanates Sulforaphane and Erucin: Characterization, Metabolism and Interconversion

Besma Abbaoui, Kenneth M Riedl, Robin A Ralston, Jennifer M Thomas-Ahner, Steven J Schwartz, Steven K Clinton, and Amir Mortazavi
The Ohio State University, Columbus, OH, 43210

Abstract

Epidemiologic evidence suggests diets rich in cruciferous vegetables, particularly broccoli, are associated with lower bladder cancer risk. Our objectives are to investigate these observations and determine the role of isothiocyanates in primary or secondary bladder cancer prevention. We initially investigate the mechanisms whereby broccoli and broccoli sprout extracts and pure isothiocyanates inhibit normal, non-invasive (RT4) and invasive (J82, UMUC3) human urothelial cell viability. Sulforaphane ($IC_{50} = 5.66 \pm 1.2 \mu M$) and erucin ($IC_{50} = 8.79 \pm 1.3 \mu M$) are found to be the most potent inhibitors and normal cells are least sensitive. This observation is associated with downregulation of survivin, EGFR and HER2/neu, G₂/M cell cycle accumulation and apoptosis. In a murine UMUC3 xenograft model, we fed semipurified diets containing 4% broccoli sprouts, or 2% broccoli sprout isothiocyanate extract; or gavaged pure sulforaphane or erucin (each at 295 $\mu mol/kg$, similar to dietary exposure); and report tumor weight reduction of 42% ($p=0.02$), 42% ($p=0.04$), 33% ($p=0.04$) and 58% ($p<0.0001$), respectively. Sulforaphane and erucin metabolites are present in mouse plasma (micromolar range) and tumor tissue, with N-acetyl cysteine conjugates as the most abundant. Interconversion of sulforaphane and erucin metabolites was observed. This work supports development of fully characterized, novel food products for phase I/II human studies targeting bladder cancer prevention.

Keywords

Bladder Cancer; Broccoli; Erucin; Isothiocyanates; Sulforaphane

Introduction

Cancer of the urinary bladder is the fifth most common neoplasm in the United States [1] and presents a significant health care burden as the most expensive cancer to treat and monitor per patient, with an annual cost of \$3.7 billion [2]. Tobacco smoking is the most important risk factor of bladder cancer and is a global concern due to expansion in tobacco use [3, 4]. The urothelium is the transitional cell epithelial lining of the bladder and is the origin of 90% of bladder cancers in the United States [5]. These transitional cell carcinomas arise and progress along two distinctive pathways representing two different clinical diseases: a “low-grade non-invasive” disease encompassing 80% of urothelial carcinomas and a “high-grade invasive” disease. The non-invasive disease is usually successfully treated

Correspondence: Amir Mortazavi, Assistant Professor, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University and The Comprehensive Cancer Center, A434A Starling-Loving Hall, 320 West 10th Ave, Columbus, OH 43210; Phone: 614-293-2886; Fax: 614-293-7520; amir.mortazavi@osumc.edu.

Disclosure of Potential Conflict of Interest: None of the authors have any potential conflicts of interest to disclose.

with surgical resection, but has a 70% recurrence rate and a 10–20% chance of progression into a high-grade invasive disease. The invasive disease has a more dismal prognosis with approximately 50% risk of death regardless of treatment [5, 6].

Bladder cancer exhibits several attributes making it an ideal target for prevention. These include its high recurrence rate, feasibility of accessing and monitoring the uroepithelium for tumors by cystoscopy, availability of predictive and diagnostic urine biomarkers [7], and the opportunity of delivering dietary components or pharmacologic chemopreventive agents through the urine, in addition to bloodstream, which may enhance anticancer activity.

Epidemiological studies support the potential role of dietary factors in bladder cancer risk, such as increased fluid intake and consumption of cruciferous vegetables, particularly broccoli [8–12]. In a large prospective cohort study, a 39% reduction in bladder cancer risk with 2 servings of broccoli/week was observed, when compared with <1 serving ($p=0.009$) [9]. Glucosinolates are the parent phytochemicals in broccoli and are converted to isothiocyanates by myrosinase, an enzyme that is released when the plant's cell structure has been disrupted through chewing, chopping, or digestion [13]. Evidence suggests that isothiocyanates are a major group of active phytochemicals in broccoli and may possess cancer inhibitory properties [14–17].

In spite of strong epidemiologic data, there are limited *in vitro* and *in vivo* studies examining the potential inhibitory effects of cruciferous vegetables and their components on specific stages of bladder carcinogenesis. Broccoli sprout extract fed at 160 $\mu\text{mol/kg/day}$ for 36 weeks of study resulted in a significant decrease in incidence, multiplicity, size, and progression of BBN-induced bladder cancer [18]. This was mainly attributed to the induction of phase II enzymes and the detoxification of the chemical carcinogen. Similarly, sulforaphane can inhibit 4-aminobiphenyl-induced DNA damage in RT4 bladder cancer cells and in mouse bladder tissue [19]. These studies, although very important, focus on broccoli isothiocyanates' ability to inhibit bladder cancer by detoxifying carcinogens and preventing DNA damage. However, it is possible that broccoli isothiocyanates may also impact bladder carcinogenesis by other mechanisms, particularly during the post-initiation phase [15]. Recently, it has been shown that allyl isothiocyanate-rich mustard seed powder can inhibit bladder cancer growth and block muscle invasion by 34.5% in an orthotopic rat model [20]. A transplantable xenograft human bladder cancer model, looking at the potential of broccoli and its isothiocyanates to inhibit bladder tumorigenesis, has not been performed. This model especially applies to the secondary prevention approach in bladder cancer, where bladder cancer is inhibited in the post-initiation phase to prevent recurrence and progression [21]. In addition, comparison of a dietary approach (broccoli sprouts and broccoli sprouts extract) with pure isothiocyanates (sulforaphane and erucin) in bladder cancer prevention and/or treatment has not been elucidated.

There is also a strong need for information on *in vivo* isothiocyanate bioavailability, distribution to target organs and tumor tissue, as well as metabolism, along with defining plasma concentrations associated with bioactivity [22]. Furthermore, studies have predominantly focused on free sulforaphane or sulforaphane-glutathione, with minimal studies focusing on other important isothiocyanates, such as erucin, and isothiocyanate metabolites produced through the mercapturic acid pathway [23, 24]. Herein, we test the efficacy of broccoli isothiocyanates both *in vitro* and *in vivo*, and assess their metabolism and tumor penetration in a xenograft murine model. We show that broccoli, broccoli sprouts, or their pure isothiocyanates inhibit the viability of specific bladder cancer cell lines, and this effect is at least in part through induction of apoptosis, modulation of cell cycle, and down-regulation of anti-apoptotic protein, survivin, and members of ErbB family receptor kinases, EGFR and HER2/neu. Next, we demonstrate that broccoli isothiocyanates, whether

administered through diet or pure gavage, lead to significant inhibition of bladder tumorigenesis in a xenograft murine model, and that erucin demonstrates greater potency. In addition, we find that broccoli isothiocyanates are readily absorbed and document that metabolites are present in mouse blood and tumor tissues. We also report the interconversion between sulforaphane and erucin metabolites *in vivo*. Our results further support the use of broccoli sprouts and/or their pure isothiocyanates in the prevention of bladder cancer and warrant further investigation in this regard.

Materials and Methods

Pure Isothiocyanates, Broccoli and Broccoli Sprout Isothiocyanate Extracts

Pure Phytochemicals—R-, S- and R,S-sulforaphane, erucin (LKT Laboratories, Inc.), allyl isothiocyanate (Sigma-Aldrich), and iberin (MP Biomedicals) were analyzed by UPLC-MS/MS for purity and quality. Treatments were prepared as stock solutions in DMSO and diluted in culture medium. The same DMSO concentration (0.1%) was used in all treatments.

Glucosinolate and Isothiocyanate Extracts for Cell Culture—Glucosinolates were extracted from organic broccoli and broccoli sprouts (BroccoSprouts®) (Whole Foods, Columbus, Ohio) [25] and quantified by LC-MS/MS, utilizing previously reported methods [26]. Isothiocyanate extracts for both broccoli and broccoli sprouts were obtained from glucosinolate extracts shaken with excess myrosinase (Sigma-Aldrich) in 95% 33 mM sodium phosphate buffer (pH 6.5–7.0, containing 2 g/L ascorbic acid and 0.01 M magnesium chloride) and 5% tetrahydrofuran (THF) for 3 hr and quantified by LC-MS/MS. Dilutions were made in THF and media, with a final THF concentration consistently at 0.125%.

Broccoli Sprout Diet Preparations for Animal Studies—Two diets were produced for the murine study. 1) Broccoli sprout isothiocyanate extract diet: Broccoli sprouts were boiled in water for 30 minutes; sprouts were then filtered out and extract was cooled. Exogenous myrosinase was added and mixture was incubated for 3.5 hr at 37°C. The mixture was flash frozen at –40°C and then lyophilized and milled into a fine powder. Total iberin, sulforaphane, and erucin were quantified by LC-MS/MS. 2) Broccoli sprout diet: Broccoli sprouts were lyophilized and then ground into a fine powder. Glucoiberin, glucoraphanin, and glucoerucin concentrations were quantified by LC-MS/MS [26]. Diets were stored at –20°C and food was changed every other day for the duration of the study.

Cell Culture

All human bladder cancer cell lines (HBCCs), RT4, J82 and UMUC3, were purchased from American Type Culture Collection (Manassas, VA) and cultured in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum, L-glutamine, penicillin, and streptomycin. Normal human bladder urothelial cells (NHU) were purchased from Cambrex Bioscience Inc. (Walkersville, MD) and cultured in serum free, keratinocyte growth medium (KGM-2 SingleQuots), supplemented with BPE, hEGF, insulin, hydrocortisone, epinephrine, transferrin, and gentamicin/amphoterecin-B. All cells were grown as monolayer cultures at 37 °C in a 95% air/5% CO₂ humidified atmosphere.

Cell Viability

Cells were seeded in quadruplicate in 96-well plates in appropriate media, at optimized cell-densities, for 1 week for NHU and 24 hr for HBCCs, before treatment. After treatment with different concentrations of phytochemicals for 48 hr (HBCCs) or 72 hr (NHU), cell viability was measured by SRB assay (Sulforhodamine B Based *In Vitro* Toxicology Assay Kit,

Sigma) per manufacturer's protocol, and percent cell viability was calculated. Optimal seeding density and the duration of treatment were determined by growth kinetics experiments, for NHU and each HBCCs, to accomplish a comparable treatment effect (data not shown).

Caspase 3/7 assay and Cell Cycle Analysis

For caspase 3/7 assay, cells were handled in 96-well plates as above, and treated with sulforaphane or erucin at 0, 5, and 10 μM concentrations for 48 hr. Caspase-3/7 activity was assessed by the Apo-ONE Homogenous Caspase-3/7 Assay (Promega) per manufacturer's protocol. For cell cycle analysis, cells were seeded overnight in culture dishes, then treated with sulforaphane or erucin at 0, 5, 10 and 20 μM concentrations for 48 hr. The cells were harvested, washed, fixed in ethanol, stained with propidium iodide, and analyzed by flow cytometry using FACSCalibur and ModFit, as previously described [27].

Western Blot Analysis

Lysates of HBCCs treated with phytochemicals, in the same way as cell cycle experiments, were prepared for immunoblotting of PARP, survivin, EGFR, HER2/neu, and GAPDH. Western blot analysis was performed as previously reported [28].

In vivo Study

Mouse xenograft studies were carried out with strict adherence to protocols approved by the Institutional Animal Care and Use Committee of The Ohio State University (Animal Protocol 2007A0167-R1; PI: A. Mortazavi). Female athymic nude mice (FOXN1^{nu} 4–5 weeks of age) were obtained from Harlan laboratories and acclimated on AIN93G pelleted diet for one week. Mice were then subcutaneously inoculated with 0.05×10^6 UMUC3, in 0.1 ml of Matrigel (BD Biosciences; 50% [v/v] in serum-free medium), in the left and right dorsal flanks. Based on our previous experience with this model and the aggressive nature of this tumor, three days after injection, mice were randomized into one of these treatment groups (12 mice/group): A1) Vehicle control soybean oil, oral gavage once daily; A2) 295 $\mu\text{mol/kg}$ body weight (bw) sulforaphane (in soybean oil), oral gavage once daily; A3) 295 $\mu\text{mol/kg}$ bw erucin (in soybean oil), oral gavage once daily; B1) Control AIN93G diet, fed *ad libitum*; B2) AIN93G diet + 4% freeze-dried broccoli sprout, fed *ad libitum*; B3) AIN93G diet + 2% freeze-dried broccoli sprout isothiocyanate extract, fed *ad libitum*. Mice were lightly anesthetized with isoflurane prior to daily gavage treatments. Mouse weights and tumor sizes were measured biweekly with tumor volume determined by using calipers and volumes calculated using the standard formula: $\text{width}^2 \times \text{length} \times 0.52$. Mice were sacrificed at 2 weeks, when tumors reached approximately 1.2 cm in diameter. At sacrifice, blood was collected and plasma isolated. Tumors were removed, measured and weighed, and bladders were also collected, with half of the tissue flash frozen in liquid nitrogen and the other half fixed overnight in 10% neutral buffered formalin and then transferred to 70% ethanol for histological use. Tumor and plasma were preserved for metabolite quantification studies in 0.2% formic acid. Two mice from each group were submitted to The Ohio State University Mouse Phenotyping Shared Resource for evaluation of gross and histologic pathology.

Histology

Formalin-fixed paraffin embedded tumor tissue from control and 4% broccoli sprout treated mice were sectioned and stained with hematoxylin and eosin (H&E). Ki67 staining was also performed per manufacturer's protocol with Ki67 primary antibody (1:50, rat monoclonal antibody, Dako Cytomation), biotinylated secondary antibodies and Vector ABC Elite kit (Vector Laboratories, Burlingame, CA) used. The percentage of positive nuclei was then

calculated based on the following formula: labeling index (%) = $L / (L+C) \times 100$, where L= labeled cells and C = counterstained, unlabeled cells.

Metabolite Quantification

Mercapturic acid pathway metabolites of sulforaphane and erucin in plasma and tumor tissue were quantified by UPLC-MS/MS. GSH-SFN, CYS-SFN and NAC-SFN were purchased from Toronto Research Chemicals. GSH-ECN, CYSGLY-SFN, CYSGLY-ECN, CYS-ECN, and NAC-ECN were synthesized as previously described [29]. Plasma samples were prepared as previously described [30], and tumor tissue samples were prepared by suspension in 10%(v/v) trifluoroacetic acid (TFA) (0°C) with probe sonication for 5 sec. and incubated at room temperature for 5 min prior to centrifugation at 20,000 g for 5 min. Supernatants were injected directly for UPLC-MS/MS quantization. UPLC Acquity BEH C18 (2.1×100mm, 1.7 μm) was used with a mobile phase of 0.1 %(v/v) formic acid in water versus 0.1 %(v/v) formic acid in acetonitrile at 0.45 mL/min, 40 °C. 5 μL inj. Mass Spectrometry HPLC eluent was interfaced without flow splitting to a triple quadrupole mass spectrometer (Quattro Ultima, Micromass, UK) via an electrospray probe operated in positive mode. Reproducible chromatography and MS response could not be achieved with free erucin and thus it was omitted from the analysis.

Statistics

Statistical significance was tested by two-tailed Student's t-test or ANOVA, followed by the Student-Newman-Keuls multiple comparisons test, using InStat software (GraphPad). Significance was set at $p < 0.05$.

Results

Quantification of glucosinolates reveals significantly higher levels in broccoli sprouts than mature broccoli

We characterized individual, intact glucosinolates in broccoli and broccoli sprouts by our previously developed LC-MS/MS method [26, 31]. Broccoli sprouts employed in our studies have 6.4-fold higher level of total combined glucosinolates, as compared to broccoli. Glucoraphanin (precursor to sulforaphane) is the predominant glucosinolate found in both broccoli and broccoli sprouts. Aliphatic glucosinolates, glucoiberin (precursor to iberin) and glucoerucin (precursor to erucin), are the second and third highest glucosinolates in broccoli sprouts. Indole glucosinolates, glucobrassicin (precursor to indole-3-carbinol) and neoglucobrassicin, are the second and third predominant glucosinolates in broccoli (Table 1).

Broccoli and broccoli sprouts isothiocyanate extracts and pure isothiocyanates significantly inhibit viability of non-invasive and invasive human bladder cancer cells (HBCCs)

Glucosinolate extracts, from either broccoli or broccoli sprouts, show no effect on the growth of HBCCs. However, isothiocyanate extracts, produced by adding exogenous myrosinase to glucosinolate extracts, cause a significant dose-dependent decrease in cell viability of both RT4 and J82 cell lines ($p < 0.01$) (Fig 1A). We show broccoli isothiocyanate extract at 7.3 μM (1g vegetable/L) causes 28% ($p = 0.003$) and 37% ($p < 0.0001$) inhibition of viability in RT4 and J82 cells, respectively. Mirroring our quantification data, (Table 1) broccoli sprout isothiocyanate extracts show stronger inhibition by vegetable weight due to their higher glucosinolate and isothiocyanate content than broccoli. In RT4 cells, 5 μM of total isothiocyanate equivalent from broccoli sprout extract (0.05 g freeze-dried broccoli sprout/L) causes 17% inhibition of cell viability ($p = 0.008$) and 100 μM (1g freeze-dried

broccoli sprout/L) causes 88% inhibition of cell viability ($p < 0.0001$). In J82 cells 10% inhibition is observed at 1 μM of broccoli sprout total isothiocyanate equivalent (0.01 g vegetable/L) ($p = 0.04$) and 82% inhibition is observed at 100 μM (1 g vegetable/L) ($p < 0.0001$). Broccoli sprout isothiocyanate extract has an IC_{50} of $21.5 \pm 1.4 \mu\text{M}$ in J82 and $22.5 \pm 1.9 \mu\text{M}$ in RT4 cells (Fig 1A). Next, we compare individual pure isothiocyanates, sulforaphane, erucin, allyl isothiocyanate and iberin, found in broccoli and broccoli sprouts, for their effects on the viability of HBCCs. Our previous experiments have shown that the optimal bladder cancer cell inhibitory effects of these compounds are achieved at 48 hours of treatment, the time-point that we choose for our *in vitro* studies. We first compare the effects of R-sulforaphane (naturally found in broccoli), S-sulforaphane, and R,S-sulforaphane (synthetic, racemic mixture) on the cell viability of HBCCs and find no difference between isomers in their inhibitory effects of HBCCs ($p > 0.8$) (data not shown). Thus, we utilize synthetic R,S-sulforaphane for all remaining experiments. Of all isothiocyanates found in broccoli and broccoli sprouts, sulforaphane is the most potent inhibitor ($\text{IC}_{50} = 5.66 \pm 1.2 \mu\text{M}$ in UMUC3 cells, 48 hr) followed by erucin ($\text{IC}_{50} = 8.79 \pm 1.3 \mu\text{M}$ in UMUC3 cells, 48 hr), and then allyl isothiocyanate and Iberin. The extent of RT4 cell viability inhibition by 20 μM of isothiocyanates at 48 hr is: sulforaphane 64% ($p < 0.001$), erucin 59% ($p < 0.001$), allyl isothiocyanate 28% ($p < 0.001$), and iberin 12% ($p < 0.001$). We see similar trends of inhibition in J82 and UMUC3 cell lines (Fig 1B). Finally, we compare a panel of HBCCs with normal human urothelial cells (NHU) to determine if isothiocyanates can selectively inhibit HBCCs over NHU. We find sulforaphane to inhibit NHU least (62% inhibition by 20 μM , and IC_{50} not reached) followed by RT4 cells ($\text{IC}_{50} = 11.2 \pm 0.3 \mu\text{M}$), then J82 cells ($\text{IC}_{50} = 7.7 \pm 1.8 \mu\text{M}$), and finally UMUC3 cells ($\text{IC}_{50} = 5.66 \pm 1.2 \mu\text{M}$). NHU cells are also least sensitive to erucin ($\text{IC}_{50} = 19 \pm 1.7 \mu\text{M}$) with increased sensitivity by RT4 cells ($\text{IC}_{50} = 16 \pm 0.8 \mu\text{M}$, with 7% more inhibition, $p = 0.02$), followed by J82 cells ($\text{IC}_{50} = 11.3 \pm 0.1 \mu\text{M}$, with 12% more inhibition than NHU, $p = 0.042$), and finally UMUC3 cells ($\text{IC}_{50} = 8.79 \pm 1.3 \mu\text{M}$, with 23% more inhibition than NHU, $p = 0.005$) (Fig 1C).

Sulforaphane and erucin induce cell cycle arrest and apoptosis in human bladder cancer cells

To elucidate potential contributing mechanisms of action by which broccoli isothiocyanates can inhibit bladder cancer cell viability, we studied the ability of these compounds to modulate the cell cycle and induce apoptosis. We first determined the effects of isothiocyanates on the cell cycle of HBCCs (48-hour treatment). We observe a significant, dose-dependent accumulation of cells in the G_2/M phase. In RT4 cells, 20 μM sulforaphane leads to a 2.6 fold increase of cells in the G_2/M phase compared to control ($p < 0.0001$) and 20 μM erucin leads to a 2.1 fold increase ($p = 0.0025$). In addition, J82 cells treated with 20 μM sulforaphane undergo a 3-fold increase of cells in the G_2/M phase ($p = 0.0006$) and a 2.7-fold increase with 20 μM erucin treatment ($p < 0.0001$), with UMUC3 cells following similar trends. Although, we observed a slight trend towards accumulation of cells in the S-phase in some of the cell lines treated with sulforaphane and/or erucin, this was not statistically significance ($p > 0.1$) (Fig 2). Treatment of HBCCs with sulforaphane and erucin also results in a significant dose-dependent increase in caspase 3/7 activity (Fig 3A) and the cleavage of their important target, PARP (Fig 3B–C), indicating the activation of apoptotic cascades. In RT4 cells, 10 μM sulforaphane treatment for 48 hr leads to a 2.5-fold increase in caspase 3/7 activity ($p = 0.003$) and 10 μM erucin leads to a 3.2-fold increase ($p < 0.0001$), as compared to control (Fig 3A). Mirroring these findings, PARP cleavage increases 2.3-fold in RT4 cells treated with 20 μM sulforaphane ($p = 0.013$) and 2-fold when treated with 20 μM erucin ($p = 0.002$). In UMUC3 cells, PARP cleavage increases 3.6-fold with 20 μM sulforaphane treatment ($p < 0.001$) and 20 μM erucin causes a 4-fold increase ($p = 0.003$) (Fig 3B–C). In addition, we studied survivin expression, an important anti-apoptotic protein and a predictor

of bladder cancer disease progression [32]. We observe a significant dose-dependent decrease in survivin expression, by sulforaphane and erucin, in all HBCCs. In RT4 cells, 20 μ M sulforaphane leads to a 51% decrease in survivin expression ($p<0.0001$) and 20 μ M sulforaphane leads to a 44% decrease ($p<0.0001$). In addition, in UMUC3 cells, survivin expression is downregulated by 35% with 20 μ M sulforaphane treatment ($p<0.0001$) and 69% with 20 μ M erucin treatment ($p=0.0003$) (Fig 3B).

Tyrosine-kinase receptors, EGFR and HER2/neu, are shown to be overexpressed in urothelial tumors and their degree of expression is also associated with cancer progression and poor prognosis [33]. Therefore, we study the ability of broccoli isothiocyanates to modulate the expression of these receptors, which may show new mechanisms of action for these compounds and may have clinical implications. Interestingly, we find that both sulforaphane and erucin significantly downregulate EGFR and HER2/neu expression in the invasive UMUC3 cell line, but not to an appreciable level in non-invasive cell line RT4. In RT4 cells, 20 μ M of sulforaphane ($p=0.11$) or erucin ($p=0.25$) does not lead to significant changes in EGFR expression. However, in UMUC3 cells, EGFR protein expression is downregulated 54% by 20 μ M sulforaphane ($p=0.01$) and 73% by 20 μ M erucin ($p=0.0002$). Furthermore, in RT4 cells, 20 μ M sulforaphane causes a 10% decrease of HER2/neu expression ($p=0.013$) and no significant changes with 20 μ M erucin ($p=0.33$). In contrast, HER2/neu is downregulated 90% in UMUC3 cells by 20 μ M sulforaphane ($p<0.0001$) and 83% by 20 μ M erucin ($p=0.001$) (Fig 3B–C). Similar trends were observed in J82 cells (data not shown). Overall, sulforaphane and erucin exhibit similar impacts on apoptosis and cell cycle progression ($p>0.1$).

Broccoli sprout isothiocyanates significantly inhibit bladder cancer *in vivo*

Observations of the inhibitory effects of broccoli isothiocyanates *in vitro*, led us to examine the relevance of our work in an *in vivo* xenograft model. We conducted two separate *in vivo* experiments to elucidate the effects of two distinct phytochemical delivery approaches, meaning a pure isothiocyanate gavage vs. a dietary administration of whole broccoli sprouts. In the gavage arm, we compared pure isothiocyanates of sulforaphane or erucin to the vehicle control; and in the dietary arm, we compared the whole broccoli sprouts or broccoli sprouts isothiocyanate extract to the control diet. We chose to use a dose of 295 μ mol sulforaphane/kg body weight based on previous xenograft studies in other cancer models showing safety and efficacy at this dose [34, 35]. Encouraged by our *in vitro* data, we chose to compare erucin's potency at an equivalent dose to sulforaphane.

We incorporated broccoli sprout isothiocyanate extract into a semipurified diet to provide a similar overall exposure as in our gavage of pure isothiocyanates. Our HPLC-MS/MS quantification shows that our broccoli sprout isothiocyanate extract contained 197 μ mol isothiocyanate/g extract with 63% sulforaphane, 28% iberin, and 8.4% erucin. Given that female athymic nude mice eat approximately 3 g diet/day and weigh on average 25 g, we mixed 2% freeze-dried broccoli sprout isothiocyanate extract into AIN93G diet so that mice would consume approximately 11.82 μ mol total isothiocyanates/day or 473 μ mol total isothiocyanates/kg body weight/day (297 μ mol/kg bw sulforaphane, 132 μ mol/kg bw Iberin, and 39.7 μ mol/kg bw erucin). We chose 2% to match our gavaged treatments of sulforaphane and erucin with total sulforaphane consumed.

A second dietary intervention provided whole freeze-dried broccoli sprouts. Our quantification of whole freeze-dried broccoli sprouts used in our animal study revealed 51 μ mol total glucosinolate/g sprout with 68.5% glucoraphanin, 21% glucoiberin, and 10.3% glucoerucin. This batch differed in phytochemical content of that quantified in Table 1, which points to the variability of glucosinolates between batches of sprouts and highlights the importance of quantification when doing experiments of this nature. We mixed 4% by

weight of broccoli sprout into AIN93G diet so mice would consume approximately 6.12 μmol total glucosinolates/day or 245 μmol total glucosinolates/kg body weight/day (171 $\mu\text{mol/kg}$ bw glucoraphanin, 51 $\mu\text{mol/kg}$ bw glucoiberin and 25.21 $\mu\text{mol/kg}$ bw glucoerucin). In this case, we matched total glucosinolates to the sulforaphane and erucin gavaged treatment concentrations we administered, as we did not want to administer an unreasonably high percentage of broccoli sprouts (4% over 8%) in mouse diet, for hopes of better translation into future human clinical trials.

By two weeks of treatment, we see a significant inhibition of UMUC3 tumor weight in all treated groups, with the greatest inhibition seen in the erucin treated group. We see a 42% decrease in final tumor weight with 2% broccoli sprout isothiocyanate extract treatment ($p=0.02$), and a 42% decrease with 4% broccoli sprout treatment ($p=0.04$), as compared to the control diet (Fig 4A). Also, we see a 33% decrease with 295 μmol sulforaphane/kg/day treatment ($p=0.04$), and a 58% decrease with 295 μmol erucin/kg/day treatment ($p<0.0001$), as compared to the vehicle control soy bean oil (Fig 4A). Tumor growth rates follow similar trends as final tumor weights; with 46% inhibition by 2% isothiocyanate extract treatment ($p=0.03$), 39% inhibition by 4% sprout treatment ($p=0.15$), 42% inhibition by sulforaphane treatment ($p=0.36$), and 82% inhibition by erucin treatment ($p=0.11$) (Fig 4A). To assess at least the minimum of proliferation inhibition *in vivo*, we chose the least inhibited treatment group (4% broccoli sprout) to perform Ki67 staining, a marker of cell proliferation, on harvested tumors and observe a 50% decrease in Ki67-positive cells ($p<0.0001$) (Fig 4B). There is no overt evidence of toxicity in serum chemistry or cell blood counts and no significant change in mouse weight between groups throughout the study ($p>0.4$).

Isothiocyanates are efficiently absorbed and metabolized, with detectable metabolites in blood and bladder tumor tissue; and sulforaphane and erucin are readily interconverted *in vivo*

Due to our observation that broccoli isothiocyanates treatment has the ability to inhibit bladder cancer growth *in vivo*, we become interested in assessing the bioavailability and metabolism of these compounds in our animal model. It is important to understand absorption and metabolism of these compounds in order to properly translate this work into future human clinical trials. We utilize UPLC-MS/MS to quantify sulforaphane and erucin metabolites in mouse plasma and tumor tissues. Metabolites of sulforaphane and erucin are absent in both control groups and present in plasma and tumors of all treated groups, with dietary and pure phytochemical treatments resulting in micromolar plasma metabolite concentrations with no significant differences between these groups ($p>0.2$). There is also significant accumulation of broccoli isothiocyanate metabolites in tumor (Fig 5A) and bladder tissues (data not shown) at picomolar range, with greatest absorption with the broccoli sprout isothiocyanate extract group over pure phytochemical treatment ($p<0.05$). N-acetylcysteine conjugates of sulforaphane and erucin are the most abundant metabolites in all ($p<0.0001$), except for the tumors in erucin-gavage group, where cysteine-erucin is the most abundant. Following N-acetylcysteine metabolites, cysteine and glutathione conjugates are present, as well as small amounts of detectable cysteinylglycine conjugates and unconjugated sulforaphane. Interestingly, we observe a robust interconversion of sulforaphane and erucin, as both metabolites were present in the plasma and tumors of mice gavaged pure individual compounds (Fig 5B–C).

Discussion

There remains a strong need for the improvement of bladder cancer prevention and treatment modalities. Our future objective is to develop a novel food product, rich in cruciferous vegetable bioactives, that can be employed in phase I/II clinical trials in those at

risk of bladder cancer or recurrence following cystoscopic removal. In order to move forward, we conducted critical preclinical studies to define relevant analytic and tissue biomarkers. Our studies demonstrate the antitumor effects of broccoli, broccoli sprouts and their pure isothiocyanates, using *in vitro* and *in vivo* models of bladder cancer. Most critically, we define the concentration of metabolites of these compounds in plasma and tumor tissue that are associated with anticancer bioactivity. A study comparing the anti-bladder cancer effects of dietary administration of whole broccoli sprouts, broccoli sprout isothiocyanate extracts or pure isothiocyanates gavage has not previously been reported. Furthermore, there has been a strong focus in the literature on the ability of isothiocyanates to induce phase II enzymes, thereby aiding in the detoxification of carcinogens and thus leading to a cancer preventive response [17, 18, 36]. However, a study on the ability of broccoli isothiocyanates, particularly sulforaphane and erucin, to inhibit the growth of established bladder cancer, outside the context of carcinogen detoxification, through the use of a human xenograft bladder cancer model has not been reported.

In order for *in vitro* and *in vivo* studies utilizing vegetable extracts to be meaningful, it is important to characterize phytochemicals present in these extracts, especially given the variation inherent in foods due to variations in genetics, growing conditions, and processing [37]. Herein, we first determine the amounts of individual glucosinolates present in broccoli and broccoli sprout extracts. The broccoli sprouts we employed show a greater than 6-fold higher isothiocyanates concentrations than broccoli [25]. Thus, broccoli sprouts are an excellent choice for developing a food product for future human studies. Furthermore, our xenograft studies show that the use of 4% freeze-dried broccoli sprout diet (containing 51 μmol glucosinolate/g) leads to the same level of tumor inhibition as the 2% broccoli sprout isothiocyanate extract diet (containing 197 μmol isothiocyanate/g), with similar resulting levels of plasma isothiocyanates. Glucosinolates in the broccoli sprouts were likely converted into active isothiocyanates as a result of the release of endogenous myrosinase during the grinding process. This suggests there may be a level of maximal absorption of glucosinolates and isothiocyanates, and that a higher dose of administration may not lead to a greater beneficial effect. Furthermore, we find broccoli sprouts to have higher concentrations of glucoerucin, the precursor to erucin, than broccoli. Interestingly, our data shows erucin to be the most potent inhibitor of bladder tumorigenesis in our xenograft model. This is a novel finding, because although erucin has been shown to induce phase II detoxification enzymes in the urinary bladder of rats [36], it has never been shown to inhibit bladder carcinogenesis.

Through our cell viability data we show broccoli and broccoli sprout glucosinolates do not have an effect on bladder cancer cell viability, while isothiocyanates do, supporting present evidence for the importance of glucosinolate conversion to isothiocyanate for their anti-cancer activity [14, 15]. Furthermore, of the major isothiocyanates found in broccoli and broccoli sprouts, we show sulforaphane and erucin are the most potent inhibitors of viability, causing significant induction of apoptosis and cell cycle arrest, which is also supported by previous work [36, 38, 39]. Our cell cycle analysis mirrors previous findings of arrest in the G₂/M and S phase through downregulation of Cdc25c and disruption of the mitotic spindle in bladder cancer cell lines treated with broccoli sprout isothiocyanate extract [40]. We also show that EGFR, HER2/neu, survivin and Ki67, important biological proteins and prognostic markers for bladder cancer disease progression [32], are significantly inhibited by broccoli isothiocyanates.

We show that broccoli isothiocyanates, whether administered through diet as whole broccoli sprouts or broccoli sprout isothiocyanate extract or through gavage as pure isothiocyanates (sulforaphane or erucin), can strongly inhibit aggressive, rapidly growing UMUC3 bladder xenograft tumor, without causing any apparent toxicity. Overall, it appears that consumption

of phytochemicals, either through pure phytochemical gavage or dietary-based administration, inhibits the bladder tumorigenesis at a fairly similar rate. Through the use of our xenograft study, we also report that broccoli isothiocyanates have the ability to inhibit bladder carcinogenesis outside the context of carcinogen detoxification and also that isothiocyanates can inhibit bladder cancer, post-initiation. Future studies should employ the use of novel transgenic models of bladder cancer [41–43] to study the potential preventive benefits of these compounds.

We also show that isothiocyanates are detectable in mouse plasma and tumor tissue when administered through diet or by gavage, indicating effective absorption and tumor penetration. The bioavailability of erucin has not been studied to date [44]. We found that erucin gavage, broccoli sprout, and broccoli sprout isothiocyanate extract groups all had comparable plasma total isothiocyanate metabolite levels (1–2 μM) and comparable tumor inhibition. Most importantly, these effective plasma levels are achievable in humans [45, 46]. For reasons that are unclear, the sulforaphane gavage group shows lower plasma concentrations (1 μM) and less tumor inhibition, although not to a significant level. Tumor metabolite levels are comparable among the groups, except the isothiocyanate extract group, which had significantly higher concentrations.

Analysis of plasma and tumor tissue, collected 12–18 hours after gavage of isothiocyanates, indicates sustained plasma and tumor levels, as supported by previous reports [18]. Interestingly, N-acetyl-L-cysteine-sulforaphane (NAC-sulforaphane) is the predominant metabolite found in both plasma and tumor tissue and NAC-erucin was the predominant metabolite found in plasma while tumors had predominantly cysteine-erucin. These thiol-conjugated isothiocyanates have been shown to dissociate into free isothiocyanates under physiologic conditions [47]. In addition, NAC-conjugated isothiocyanates are the predominant urinary metabolite of dietary isothiocyanates and have been shown to be equally potent at inhibiting human bladder cancer cell proliferation as free isothiocyanates [48]. Interestingly, the concentrations of broccoli isothiocyanate metabolites in tumor and bladder tissues are in the picomolar range, and yet biologically active, they are significantly less than the effective concentrations needed for *in vitro* experiments (micromolar range). This observation is very important for future animal and human studies. We also observe a robust interconversion of sulforaphane and erucin which has previously been reported in two rat studies and has been shown to occur in humans [49–51]. Erucin was partially converted to sulforaphane by oxidation reaction and sulforaphane to erucin by reduction reaction. Both species are present when either is administered, suggesting equilibrium between these two forms. We were unable to detect appreciable interconversion of these compounds *in vitro* (data not shown), supporting that this is largely an *in vivo* phenomenon. The cause and biological effects of the robust interconversion between sulforaphane and erucin *in vivo*, which may occur by liver metabolism or conversion by gut microflora, deserves further study.

Overall, we report that broccoli and broccoli sprout isothiocyanates, especially sulforaphane and erucin, can significantly inhibit bladder cancer growth both *in vitro* and *in vivo*. These compounds are readily bioavailable and their active metabolites can be detected in plasma and tumor tissues. This work supports continued preclinical research including prevention studies in murine transgenic models of human bladder cancer. This work also supports the development of novel food products, with a particular focus upon broccoli sprouts and the use of sophisticated processing techniques to enhance conversion of glucosinolates to active components. In addition, future clinical studies can include *primary prevention*, in high risk patients, such as heavy smokers; and *secondary prevention*, to decrease the rate of recurrence and progression of disease in established bladder cancer patients. Human

investigations, should they show positive results, will significantly contribute to improving patients' outcomes, saving lives, and lowering health care costs.

Acknowledgments

We thank Robert Rengel, Sanjay Bhawe, Jun-Ge Yu, and Valerie DeGroff for technical support.

Funding Support: NIH/NCCAM F31AT006486, NIH/NIGMS 5T32GM068412-04, NIH/NCI OSU CCC P30 CA16058, Shoen Cancer Prevention Research Fund; Center for Functional Foods and Research Entrepreneurship (CAFFRE).

Abbreviations

Allyl ITC	allyl isothiocyanate
ANOVA	analysis of variance
BBN	N-butyl-N-(4 hydroxybutyl) nitrosamine
BPE	bovine pituitary extract
CYS	cysteine
CYSGLY	cysteinyl glycine
ECN	erucin
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
GAPDH	glyceraldehyde 3-phosphate dehydrogenase
GSH	glutathione
H&E	hematoxylin & eosin
HBCC	human bladder cancer cell line
hEGF	human epidermal growth factor
HER2/neu	human epidermal growth factor receptor 2
NAC	N-acetyl-L-cysteine
NHU	normal human bladder urothelial cells
SFN	sulforaphane
SRB	sulforhodamine B assay
UPLC-MS/MS	Ultra performance liquid chromatography-mass spectrometry/mass spectrometry

References

1. Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. *CA Cancer J Clin.* 61:69–90. [PubMed: 21296855]
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. *Pharmacoeconomics.* 2003; 21:1315–1330. [PubMed: 14750899]
3. Guindon, GE. WHO Tobacco Control Papers. Center for Tobacco Control Research and Education; UC San Francisco: 2003. Boisclair, David, Past, Current and Future Trends in Tobacco Use. <http://escholarship.org/uc/item/4q57d5vp>

4. Augustine A, Hebert JR, Kabat GC, Wynder EL. Bladder cancer in relation to cigarette smoking. *Cancer Res.* 1988; 48:4405–4408. [PubMed: 3390836]
5. Crawford JM. The origins of bladder cancer. *Lab Invest.* 2008; 88:686–693. [PubMed: 18475256]
6. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. *Nat Rev Cancer.* 2005; 5:713–725. [PubMed: 16110317]
7. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? *CA Cancer J Clin.* 60:244–272. [PubMed: 20566675]
8. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, et al. Fluid intake and the risk of bladder cancer in men. *N Engl J Med.* 1999; 340:1390–1397. [PubMed: 10228189]
9. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, et al. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. *J Natl Cancer Inst.* 1999; 91:605–613. [PubMed: 10203279]
10. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, et al. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. *Am J Epidemiol.* 2000; 152:1145–1153. [PubMed: 11130620]
11. Michaud DS, Clinton SK, Rimm EB, Willett WC, Giovannucci E. Risk of bladder cancer by geographic region in a U.S. cohort of male health professionals. *Epidemiology.* 2001; 12:719–726. [PubMed: 11679802]
12. Tang L, Zirpoli GR, Guru K, Moysich KB, et al. Intake of cruciferous vegetables modifies bladder cancer survival. *Cancer Epidemiol Biomarkers Prev.* 19:1806–1811. [PubMed: 20551305]
13. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. *Cancer Epidemiol Biomarkers Prev.* 2001; 10:501–508. [PubMed: 11352861]
14. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. *Proc Natl Acad Sci U S A.* 1997; 94:10367–10372. [PubMed: 9294217]
15. Wu X, Zhou QH, Xu K. Are isothiocyanates potential anti-cancer drugs? *Acta Pharmacol Sin.* 2009; 30:501–512. [PubMed: 19417730]
16. Hecht SS. Inhibition of carcinogenesis by isothiocyanates. *Drug Metab Rev.* 2000; 32:395–411. [PubMed: 11139137]
17. Zhang Y, Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. *Cancer Res.* 1994; 54:1976s–1981s. [PubMed: 8137323]
18. Munday R, Mhawech-Fauceglia P, Munday CM, Paonessa JD, et al. Inhibition of urinary bladder carcinogenesis by broccoli sprouts. *Cancer Res.* 2008; 68:1593–1600. [PubMed: 18310317]
19. Ding Y, Paonessa JD, Randall KL, Argoti D, et al. Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and tissues. *Carcinogenesis.* 31:1999–2003. [PubMed: 20810543]
20. Bhattacharya A, Tang L, Li Y, Geng F, et al. Inhibition of bladder cancer development by allyl isothiocyanate. *Carcinogenesis.* 31:281–286. [PubMed: 19955395]
21. Duggan BJ, Gray SB, McKnight JJ, Watson CJ, et al. Oligoclonality in bladder cancer: the implication for molecular therapies. *J Urol.* 2004; 171:419–425. [PubMed: 14665946]
22. Lamy E, Scholtes C, Herz C, Mersch-Sundermann V. Pharmacokinetics and pharmacodynamics of isothiocyanates. *Drug Metab Rev.*
23. Egner PA, Kensler TW, Chen JG, Gange SJ, et al. Quantification of sulforaphane mercapturic acid pathway conjugates in human urine by high-performance liquid chromatography and isotope-dilution tandem mass spectrometry. *Chem Res Toxicol.* 2008; 21:1991–1996. [PubMed: 18729326]
24. Clarke JD, Hsu A, Williams DE, Dashwood RH, et al. Metabolism and Tissue Distribution of Sulforaphane in Nrf2 Knockout and Wild-Type Mice. *Pharm Res.*
25. Mellon FA, Bennett RN, Holst B, Williamson G. Intact glucosinolate analysis in plant extracts by programmed cone voltage electrospray LC/MS: performance and comparison with LC/MS/MS methods. *Anal Biochem.* 2002; 306:83–91. [PubMed: 12069418]
26. Tian Q, Rosselot RA, Schwartz SJ. Quantitative determination of intact glucosinolates in broccoli, broccoli sprouts, Brussels sprouts, and cauliflower by high-performance liquid chromatography-

- electrospray ionization-tandem mass spectrometry. *Anal Biochem.* 2005; 343:93–99. [PubMed: 15963940]
27. Zhou JR, Gugger ET, Tanaka T, Guo Y, et al. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. *J Nutr.* 1999; 129:1628–1635. [PubMed: 10460196]
 28. Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. *J Nutr.* 2003; 133:2367–2376. [PubMed: 12840208]
 29. Vermeulen M, Zwanenburg B, Chittenden GJF, Verhagen H. Synthesis of isothiocyanate-derived mercapturic acids. *European J Medicinal Chem.* 2003; 38:729–737.
 30. Al Janobi AA, Mithen RF, Gasper AV, Shaw PN, et al. Quantitative measurement of sulforaphane, iberin and their mercapturic acid pathway metabolites in human plasma and urine using liquid chromatography-tandem electrospray ionisation mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2006; 844:223–234.
 31. Tian Q, Rosselot RA, Schwartz SJ. Quantitative determination of intact glucosinolates in broccoli, broccoli sprouts, Brussel sprouts, and cauliflower by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. *Anal Biochem.* 2005; 343:93–99. [PubMed: 15963940]
 32. Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, et al. Current status of prognostic immunohistochemical markers for urothelial bladder cancer. *Tumour Biol.* 2008; 29:311–322. [PubMed: 18984977]
 33. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. *Crit Rev Oncol Hematol.* 2003; 46(Suppl):S85–104. [PubMed: 12850530]
 34. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. *Exp Biol Med (Maywood).* 2007; 232:227–234. [PubMed: 17259330]
 35. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. *Carcinogenesis.* 2004; 25:83–90. [PubMed: 14514658]
 36. Munday R, Munday CM. Induction of phase II detoxification enzymes in rats by plant-derived isothiocyanates: comparison of allyl isothiocyanate with sulforaphane and related compounds. *J Agric Food Chem.* 2004; 52:1867–1871. [PubMed: 15053522]
 37. Fahey JW, Zalcman AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. *Phytochemistry.* 2001; 56:5–51. [PubMed: 11198818]
 38. Shan Y, Sun C, Zhao X, Wu K, et al. Effect of sulforaphane on cell growth, G(0)/G(1) phase cell progression and apoptosis in human bladder cancer T24 cells. *Int J Oncol.* 2006; 29:883–888. [PubMed: 16964384]
 39. Tang L, Zhang Y. Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells. *Mol Cancer Ther.* 2005; 4:1250–1259. [PubMed: 16093441]
 40. Tang L, Zhang Y, Jobson HE, Li J, et al. Potent activation of mitochondria-mediated apoptosis and arrest in S and M phases of cancer cells by a broccoli sprout extract. *Mol Cancer Ther.* 2006; 5:935–944. [PubMed: 16648564]
 41. Buckley MT, Yoon J, Yee H, Chiriboga L, et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. *J Transl Med.* 2007; 5:49. [PubMed: 17935615]
 42. Wu XR, Lin JH, Walz T, Haner M, et al. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. *J Biol Chem.* 1994; 269:13716–13724. [PubMed: 8175808]
 43. Zhang ZT, Pak J, Huang HY, Shapiro E, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. *Oncogene.* 2001; 20:1973–1980. [PubMed: 11360181]
 44. Traka, AMaMH. Biological Profile of Erucin: A New Promising Anticancer Agent from Cruciferous Vegetables. *Toxins.* 2010; 2:593–612. [PubMed: 22069601]

45. Conaway CC, Getahun SM, Liebes LL, Pusateri DJ, et al. Disposition of glucosinolates and sulforaphane in humans after ingestion of steamed and fresh broccoli. *Nutr Cancer*. 2000; 38:168–178. [PubMed: 11525594]
46. Clarke JD, Hsu A, Riedl K, Bella D, et al. Bioavailability and inter-conversion of sulforaphane and erucin in human subjects consuming broccoli sprouts or broccoli supplement in a cross-over study design. *Pharmacol Res*. 2011; 64:456–463. [PubMed: 21816223]
47. Conaway CC, Krzeminski J, Amin S, Chung FL. Decomposition rates of isothiocyanate conjugates determine their activity as inhibitors of cytochrome p450 enzymes. *Chem Res Toxicol*. 2001; 14:1170–1176. [PubMed: 11559030]
48. Tang L, Li G, Song L, Zhang Y. The principal urinary metabolites of dietary isothiocyanates, N-acetylcysteine conjugates, elicit the same anti-proliferative response as their parent compounds in human bladder cancer cells. *Anticancer Drugs*. 2006; 17:297–305. [PubMed: 16520658]
49. Kassahun K, Davis M, Hu P, Martin B, Baillie T. Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. *Chem Res Toxicol*. 1997; 10:1228–1233. [PubMed: 9403174]
50. Bheemreddy RM, Jeffery EH. The metabolic fate of purified glucoraphanin in F344 rats. *J Agric Food Chem*. 2007; 55:2861–2866. [PubMed: 17367161]
51. Vermeulen M, van den Berg R, Freidig AP, van Bladeren PJ, Vaes WH. Association between consumption of cruciferous vegetables and condiments and excretion in urine of isothiocyanate mercapturic acids. *J Agric Food Chem*. 2006; 54:5350–5358. [PubMed: 16848516]

Figure 1. Broccoli and broccoli sprout isothiocyanates significantly inhibit viability of human bladder cancer cell lines (HBCCs)

Growth inhibitory effects of broccoli and broccoli sprout glucosinolates and enzymatically-hydrolyzed glucosinolates (isothiocyanates) and pure isothiocyanates are assessed by sulforhodamine B (SRB) assay. **A.** The effects of glucosinolate and isothiocyanate extracts from broccoli and broccoli sprouts on the cell viability of RT4 (non-invasive) and J82 (invasive) HBCCs. Serial dilutions of broccoli and broccoli glucosinolate and isothiocyanate extracts are prepared and total glucosinolate and isothiocyanate equivalents calculated based on HPLC-MS/MS quantification (1 g freeze-dried broccoli/L=14.3 μM glucosinolate equivalent and 7.28 μM isothiocyanate equivalent; 1 g freeze-dried broccoli sprouts/L = 100 μM glucosinolate equivalent and 100 μM isothiocyanate equivalent). Broccoli treatments include 0.00728, 0.0728, 0.364, 0.728, 1.82, 3.64 and 7.28 μM isothiocyanate equivalents and broccoli sprout treatments include 0.1, 1, 5, 10, 25, 50 and 100 μM isothiocyanate equivalents. Treatments are performed for 48 hours. **B.** The most abundant isothiocyanates found in broccoli and broccoli sprout isothiocyanate extracts, sulforaphane (SFN), erucin (ECN), allyl isothiocyanate (Allyl ITC), and iberin, are compared for antiproliferative effects in RT4 (non-invasive), and J82 and UMC3 (invasive) HBCCs. Doses of 0, 0.5, 1, 2.5, 5, 10, 20 μM are used for 48 hours of treatment. **C.** Comparative inhibition of cell viability by sulforaphane and erucin in normal human urothelial/bladder cells (NHU) and a panel of HBCCs ranging from non-invasive low-grade (RT4) to invasive high-grade (J82 and UMC3). NHU are treated for 72 hours and HBCCs treated for 48 hours, to adjust for the difference in the growth curves of these cells. Points = means; bars = ±SD, (n = 3).

Figure 2. Sulforaphane and erucin treatment leads to accumulation of human bladder cancer cell lines in the G₂/M phase of the cell cycle
 RT4 (non-invasive low-grade) and J82 and UMUC3 (invasive high-grade) human bladder cancer cells are treated with vehicle control (DMSO) or 5, 10 and 20 μM of sulforaphane (SFN) or erucin (ECN) for 48 hours and then stained with propidium iodide for cell cycle analysis through flow cytometry. A significant dose-dependent accumulation of cells in the G₂/M phase is observed. Each histogram is representative of three independent experiments, and each was done in duplicate samples. (n = 3), *p<0.05.

Figure 3. Induction of apoptosis and modulation of ErbB family of receptors by sulforaphane and erucin in human bladder cancer cell lines

Non-invasive (RT4) and invasive (UMUC3) bladder cancer cells are treated with vehicle control (DMSO) or 5, 10 and 20 μM of sulforaphane (SFN) or erucin (ECN) for 48 hours. **A.** Dose-dependent induction of apoptosis by sulforaphane and erucin, is evident by caspase 3/7 activity. Points = means; bars = $\pm\text{SD}$, ($n = 3$), $*p < 0.05$. **B.** Western blot analysis of dose-dependent effects of sulforaphane and erucin on PARP cleavage, and expression of survivin, EGFR and HER2/neu. Each immunoblot is representative of three independent experiments. **C.** Relative expression levels of cleaved PARP, survivin, EGFR and HER2/neu. Amounts of immunoblotted proteins were quantified by densitometry and normalized against that of GAPDH. Points = means; bars = $\pm\text{SD}$, ($n = 3$), $*p < 0.05$.

Figure 4. Broccoli sprouts and their isothiocyanates cause inhibition of bladder cancer *in vivo* Female athymic nude mice (n=12/group) were injected with UMUC3 (invasive) human bladder cancer cells in each flank and later randomized to one of these treatment groups: A1) Vehicle control soybean oil, oral gavage once daily; A2) 295 μ mol/kg body weight sulforaphane (SFN) (in soybean oil), oral gavage once daily; A3) 295 μ mol/kg body weight erucin (ECN) (in soybean oil), oral gavage once daily; or B1) control AIN93G diet, fed *ad libitum*; B2) AIN93G diet + 2% freeze-dried broccoli sprout isothiocyanate extract, fed *ad libitum*; B3) AIN 93 G diet + 4% freeze-dried broccoli sprout, fed *ad libitum*; for 2 weeks. **A.** At sacrifice, tumors are harvested and weighed. Box plots represent final tumor weights, with plus signs indicating means. Tumor growth rates (mm³/day) are also quantified during the course of treatment. Error bars for tumor weight represent standard deviation and for growth rate represent standard error (for means, *p<0.05, ***p<0.001). **B.** Tumors from control diet and 4% broccoli sprout diet treated mice are stained with hematoxylin and eosin (H&E) showing tumor morphology or Ki67 (cell proliferation marker) with background hematoxylin stain, images are at 400X magnification. Proliferative index is the percentage of Ki67 stained cells. Data represents six independent samples, with 3 image fields counted per sample and error bars represent standard deviation (*p<0.05, n=6).

Figure 5. Broccoli isothiocyanates are efficiently absorbed, metabolized and penetrated tumors and sulforaphane and erucin are readily interconverted

Total and individual isothiocyanate metabolites are quantified by UPLC-MS/MS in plasma and UMUC3 tumors from our xenograft study. **A.** The sum of all sulforaphane (SFN) and erucin (ECN) metabolites is represented in each group (μM/mL supernatant). **B.** Analysis of sulforaphane metabolites through the mercapturic acid pathway in dietary and gavaged treatment groups in plasma and tumor tissue. Evidence of interconversion of erucin into sulforaphane metabolites is apparent in gavaged treatment groups. **C.** Analysis of erucin metabolites through the mercapturic acid pathway in gavaged treatment groups in plasma and tumor tissue also reveals robust interconversion of sulforaphane into erucin. Data represents at least 4 mice with error bars representing standard error (*p<0.05)

GSH=glutathione, CYSGLY=cysteinyl glycine, CYS=cysteine, NAC=N-acetyl cysteine conjugates.

Table 1
 Characterization of glucosinolates in broccoli and broccoli sprout extracts, as quantified by HPLC-MS/MS.

Glucosinolate	Corresponding ITC	Broccoli		Broccoli Sprout	
		$\mu\text{mol/g dry}$	% of total	$\mu\text{mol/g dry}$	% of total
Glucoraphanin	Sulforaphane	8.53	64.4	44.5	52.6
Glucobriferin	Iberin	0.03	0.23	21.3	25.2
Singrin	Allyl ITC	0.00	0.00	0.51	0.60
Glucorucin	Erucin	0.01	0.08	9.02	10.7
Glucobrassicin	Indole-3-carbinol	2.19	16.5	0.54	0.64
Progoitrin	n/a	0.00	0.00	3.08	3.64
Gluconapin	n/a	0.15	1.11	1.34	1.59
Glucoalysin	n/a	0.06	0.45	0.06	0.08
Neoglucobrassicin	n/a	1.9	14.3	1.96	2.31
4-methoxy glucobrassicin	n/a	0.41	3.08	1.54	1.82
Gluconapoleiferin	n/a	0.02	0.15	0.76	0.90
Total		13.3	100	84.6	100

Values represent the mean of two samples.